All In Biotech

Drug Trial Radar · NCT00960141

A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Fall Study

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 829 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

829

Actual

Start

Aug 2000

Primary completion

Oct 2000

Study completion Nov 2000

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • montelukast sodiumDrug

    montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks

  • Comparator: loratadineDrug

    loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks

  • Comparator: placeboDrug

    placebo tablet, taken orally once daily at bed time for 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Daytime Nasal Symptoms ScoreTime frame: Baseline and Week 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.